FDA Approval Alert: The Need-to-Know | Nivolumab Plus Cisplatin/Gemcitabine for Unresectable Urothelial Carcinoma

In March 2024, the FDA granted accelerated approval to nivolumab plus cisplatin and gemcitabine as first-line treatment for patients with unresectable or metastatic urothelial carcinoma.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Nivolumab/Chemo Approval Adds Options for Urothelial Carcinoma, Expert Says
Video
Mar 14, 2024 4:00 PM
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
FDA Approves First-line Nivolumab Combo for Urothelial Carcinoma
Article
Mar 7, 2024 5:05 PM
Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.